Name: UMIN ID:
Unique ID issued by UMIN | UMIN000012263 |
---|---|
Receipt number | R000014333 |
Scientific Title | A Multinational, Randomized, Phase III Study of XELIRI with/without Bevacizumab versus FOLFIRI with/without Bevacizumab as Second-line Therapy in Patients with Metastatic Colorectal Cancer. |
Date of disclosure of the study information | 2013/11/11 |
Last modified on | 2019/02/22 13:33:58 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2013/11/11 14:12:06 | ||
2 | Update | 2013/12/12 12:22:10 | Recruitment status |
|
3 | Update | 2014/03/14 17:24:56 | Institutions |
|
4 | Update | 2015/05/12 14:56:42 | Last name of lead principal investigator Last name of lead principal investigator Organization Organization Division name Address Address TEL Institutions |
|
5 | Update | 2015/05/12 16:12:04 | Email |
|
6 | Update | 2016/02/02 16:02:43 | Recruitment status Last follow-up date |
|
7 | Update | 2019/02/22 13:33:58 | Recruitment status Date of closure to data entry Date trial data considered complete Date analysis concluded Publication of results URL related to results and publications |